{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=119",
    "query": {
      "condition": "Phase II",
      "page": 119
    },
    "page_size": 10
  },
  "pagination": {
    "page": 119,
    "page_size": 10,
    "total_count": 21420,
    "total_pages": 2142,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=120&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+II&page=118&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T09:38:56.700Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04160091",
      "title": "Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Shoulder",
        "Adhesive Capsulitis"
      ],
      "interventions": [
        {
          "name": "FX006",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 19,
      "start_date": "2019-11-07",
      "completion_date": "2020-06-15",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04160091"
    },
    {
      "nct_id": "NCT00410618",
      "title": "Neurological Effects of Chemotherapy and Radiation Therapy in Patients With Colon Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cognitive/Functional Effects",
        "Colorectal Cancer",
        "Long-term Effects Secondary to Cancer Therapy in Adults"
      ],
      "interventions": [
        {
          "name": "cognitive assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of Arizona",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 42,
      "start_date": "2003-04",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00410618"
    },
    {
      "nct_id": "NCT04131413",
      "title": "HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Papillomavirus Type 16",
        "Cervical Intraepithelial Neoplasia Grade II",
        "Cervical Intraepithelial Neoplasia, Grade III"
      ],
      "interventions": [
        {
          "name": "pNGVL4aCRTE6E7L2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "19 Years and older · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2020-09-14",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04131413"
    },
    {
      "nct_id": "NCT00336960",
      "title": "Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "celecoxib",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "tumor biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2002-07",
      "completion_date": "2008-03",
      "has_results": false,
      "last_update_posted_date": "2013-03-05",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336960"
    },
    {
      "nct_id": "NCT06079320",
      "title": "A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infection"
      ],
      "interventions": [
        {
          "name": "Sisunatovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2023-12-08",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-11-10",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 14,
      "location_summary": "Garden Grove, California • Westminster, California • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Mt. Dora",
          "state": "Florida"
        },
        {
          "city": "Mt. Dora",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06079320"
    },
    {
      "nct_id": "NCT00249782",
      "title": "A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Vehicle control, 2x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 2x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 1x/day",
          "type": "DRUG"
        },
        {
          "name": "MetroGel® (metronidazole gel), 1.0% 1x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2005-11",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2011-05-30",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00249782"
    },
    {
      "nct_id": "NCT01832259",
      "title": "A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2013-08",
      "completion_date": "2018-08-09",
      "has_results": true,
      "last_update_posted_date": "2018-12-12",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01832259"
    },
    {
      "nct_id": "NCT00001989",
      "title": "A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Trichosanthin",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genelabs Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Miami, Florida • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001989"
    },
    {
      "nct_id": "NCT06987968",
      "title": "A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Encephalopathy",
        "Acute on Chronic Liver Failure (ACLF)",
        "Decompensated Cirrhosis"
      ],
      "interventions": [
        {
          "name": "VS-01 on top of SOC (Active Treatment Group)",
          "type": "DRUG"
        },
        {
          "name": "SOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genfit",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 3,
      "start_date": "2025-08-25",
      "completion_date": "2025-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06987968"
    },
    {
      "nct_id": "NCT00886691",
      "title": "Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GOG Foundation",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2010-12-27",
      "completion_date": "2015-03-23",
      "has_results": true,
      "last_update_posted_date": "2022-02-04",
      "last_synced_at": "2026-11-17T09:38:56.700Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Burbank, California • Los Angeles, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00886691"
    }
  ]
}